GSK hires computational drug design expert Dr Kim Branson as new head of machine learning and AI

British multinational GlaxoSmithKline have hired computational drug design expert Dr Kim Branson as the company's new Senior Vice President, Global Head of Artificial Intelligence and Machine Learning. In his new role, the biotech veteran will oversee projects which use AI to identify novel targets for potential medicines. Dr Branson brings to the role more than 15 years' worth of experience in biotech and academia having held positions at a number of Silicon Valley firms including Gliimpse, Lumia and Hessian Informatics. Having graduated with a BSc in Biochemistry from the University of Adelaide in 1999, Dr Branson completed a PhD in Computational Drug Design at the University of Melbourne in 2003. Following graduation Dr Branson took on a role at the Australian government's Commonwealth Scientific and Industrial Research Organisation (CSIRO) organisation before moving to Stanford University to do postdoctoral research.